Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now

Page 2 of 12

11. Biogen Inc. (NASDAQ:BIIB)

Number of Hedge Fund Holders: 52

Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases worldwide. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).

The company has an elaborate product portfolio for MS, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. It also markets SPINRAZA to treat SMA, SKYCLARYS for the treatment of Friedreich’s Ataxia, and other drugs. The company takes the 11th spot on our list of the best pharma stocks to buy now.

On May 1, analyst Marc Goodman from Leerink Partners maintained a Buy rating on the stock with a $260.00 price target, supported by the company’s strong fiscal Q1 2025 performance and positive outlook on international sales.

Biogen Inc. (NASDAQ:BIIB) demonstrated resilience in positive developments in Skyclarys, Leqembi, and Spinraza products outside the US. The analyst considers this international trend a significant strength for the company, as a significant portion of its revenue is anticipated to come from outside the US.

The analyst expressed optimism for Biogen Inc.’s (NASDAQ:BIIB) future operations despite its challenges in the US market, especially with Skyclarys and Leqemb. It has significant potential for growth, supported by factors such as the expected approval of new treatments and diagnostics for Alzheimer’s disease and promising pipeline developments like BIIB080 and Litifilimab.

Page 2 of 12